Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T15:51:33.713Z.
Calculation as of: 2026-10-06T15:51:33.713Z.
Quote observation: 2026-10-06T15:49:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Gain Therapeutics, Inc.
Market Cap
$74.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$76.47M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$77.80M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$70.25M
Operating Cash Flow Yield
N/A
TTM Avg
0.41%
3Y Avg
0.41%
5Y Avg
0.41%
Market Cap
$69.18M
Operating Cash Flow Yield
182.01%
TTM Avg
137.45%
3Y Avg
137.45%
5Y Avg
137.45%
Market Cap
$78.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$67.80M
Operating Cash Flow Yield
N/A
TTM Avg
6.78%
3Y Avg
5.38%
5Y Avg
6.29%
Market Cap
$80.04M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $74.00M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $76.47M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.47M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.80M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $70.25M | N/A | 0.41% | 0.41% | 0.41% |
| Fortress Biotech, Inc. (FBIO)vs › | $69.18M | 182.01% | 137.45% | 137.45% | 137.45% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $67.80M | N/A | 6.78% | 5.38% | 6.29% |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $82.26M | N/A | 0.15% | 0.15% | 0.15% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
